MX9200727A - Composicion farmaceutica para detener el desarrollcomposicion farmaceutica para detener el desarrollo o para retardar el avance progresivo el lupus ero o para retardar el avance progresivo del lupus eritomatoso sistemico en un mamifero. itomatoso sistemico en un mamifero. - Google Patents

Composicion farmaceutica para detener el desarrollcomposicion farmaceutica para detener el desarrollo o para retardar el avance progresivo el lupus ero o para retardar el avance progresivo del lupus eritomatoso sistemico en un mamifero. itomatoso sistemico en un mamifero.

Info

Publication number
MX9200727A
MX9200727A MX9200727A MX9200727A MX9200727A MX 9200727 A MX9200727 A MX 9200727A MX 9200727 A MX9200727 A MX 9200727A MX 9200727 A MX9200727 A MX 9200727A MX 9200727 A MX9200727 A MX 9200727A
Authority
MX
Mexico
Prior art keywords
delay
pharmaceutical composition
lupus
systemic
stop development
Prior art date
Application number
MX9200727A
Other languages
English (en)
Inventor
Linda Marie Warner Lind Warner
Laurel Moore Adams Laure Adams
Original Assignee
American Home Products Corp Am
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp Am filed Critical American Home Products Corp Am
Publication of MX9200727A publication Critical patent/MX9200727A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
MX9200727A 1991-02-22 1992-02-21 Composicion farmaceutica para detener el desarrollcomposicion farmaceutica para detener el desarrollo o para retardar el avance progresivo el lupus ero o para retardar el avance progresivo del lupus eritomatoso sistemico en un mamifero. itomatoso sistemico en un mamifero. MX9200727A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/660,470 US5078999A (en) 1991-02-22 1991-02-22 Method of treating systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
MX9200727A true MX9200727A (es) 1992-09-01

Family

ID=24649665

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9200727A MX9200727A (es) 1991-02-22 1992-02-21 Composicion farmaceutica para detener el desarrollcomposicion farmaceutica para detener el desarrollo o para retardar el avance progresivo el lupus ero o para retardar el avance progresivo del lupus eritomatoso sistemico en un mamifero. itomatoso sistemico en un mamifero.

Country Status (21)

Country Link
US (1) US5078999A (es)
EP (1) EP0572542B9 (es)
KR (1) KR100201517B1 (es)
AT (1) ATE202938T1 (es)
AU (1) AU664545B2 (es)
CA (1) CA2103568A1 (es)
CY (1) CY2305B1 (es)
DE (1) DE69231927T2 (es)
DK (1) DK0572542T3 (es)
ES (1) ES2157901T3 (es)
GR (1) GR3036477T3 (es)
HK (1) HK1011281A1 (es)
HU (1) HUT70489A (es)
IE (1) IE920556A1 (es)
IL (1) IL100904A (es)
MX (1) MX9200727A (es)
NZ (1) NZ241671A (es)
PT (1) PT100145B (es)
SG (1) SG52404A1 (es)
WO (1) WO1992014477A1 (es)
ZA (1) ZA921210B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5221670A (en) * 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5286731A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory bowel disease
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease
US5164399A (en) * 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5262424A (en) * 1992-02-18 1993-11-16 American Home Products Corporation Composition of sulfonylcarbamates of rapamycin and method of treating diseases requiring immunosuppression therewith
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
DE69302945T2 (de) 1992-03-27 1996-10-10 American Home Prod 29-Demethoxyrapamycin zur Induktion der Immunosuppression
US5288711A (en) * 1992-04-28 1994-02-22 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) * 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5260300A (en) * 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) * 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
WO2001068133A1 (en) * 2000-03-14 2001-09-20 Genetics Institute, Inc. Use of rapamycin and agents that inhibit b7 activity in immunomodulation
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1319008B1 (en) 2000-09-19 2008-10-15 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
ZA200603888B (en) * 2001-06-01 2007-05-30 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
CA2455308A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin 29-enols
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
RU2344821C2 (ru) 2002-07-30 2009-01-27 Уайт Парентеральные композиции, содержащие гидроксиэфиры рапамицина
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
PT1539157E (pt) 2002-09-18 2013-10-04 Univ Pennsylvania Rapamicina para utilização na inibição ou prevenção de neovascularização coroidal
AU2003301348A1 (en) * 2002-10-18 2004-05-04 Wyeth Compositions and methods for diagnosing and treating autoimmune disease
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
BRPI0409632A (pt) * 2003-04-22 2006-04-25 Wyeth Corp combinações antineoplásticas
US7585517B2 (en) * 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
DE602005010228D1 (de) * 2004-04-14 2008-11-20 Wyeth Corp Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
KR20070083941A (ko) * 2004-10-04 2007-08-24 큐엘티 유에스에이, 인코포레이티드 중합체 전달 조성을 갖는 눈 전달
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
JP2008530145A (ja) * 2005-02-15 2008-08-07 ワイス 経口投与可能なcci−779製剤
CN101360495B (zh) 2005-11-14 2012-03-14 阿里亚德医药股份有限公司 对癌症病人给药mTOR抑制剂
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
CA2645488C (en) * 2006-03-23 2014-09-02 Macusight, Inc. Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
CA2660690A1 (en) * 2006-08-22 2008-02-28 Novartis Ag Treatment of fibrosing disorders
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
BRPI0919794A2 (pt) * 2008-10-03 2015-12-15 Elixir Medical Corp dispositivo para uso intracorpóreo, e, composto
CA2937492C (en) 2008-11-11 2019-08-13 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
EA023244B1 (ru) * 2009-04-10 2016-05-31 Хаян Ки Способ предотвращения старения клеток
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2906214A1 (en) 2012-10-12 2015-08-19 The Board of Regents of The University of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
ES2900426T3 (es) 2013-12-31 2022-03-16 Rapamycin Holdings Llc Preparaciones orales y uso de nanopartículas de rapamicina

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) * 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体

Also Published As

Publication number Publication date
IL100904A (en) 1995-10-31
US5078999A (en) 1992-01-07
NZ241671A (en) 1997-06-24
DE69231927D1 (de) 2001-08-16
ES2157901T3 (es) 2001-09-01
AU1469192A (en) 1992-09-15
CA2103568A1 (en) 1992-08-23
KR100201517B1 (ko) 1999-06-15
SG52404A1 (en) 1998-09-28
PT100145B (pt) 1999-06-30
WO1992014477A1 (en) 1992-09-03
ZA921210B (en) 1993-08-19
DE69231927T2 (de) 2001-11-22
DK0572542T3 (da) 2001-09-17
ATE202938T1 (de) 2001-07-15
KR930703001A (ko) 1993-11-29
GR3036477T3 (en) 2001-11-30
EP0572542A1 (en) 1993-12-08
CY2305B1 (en) 2003-07-04
EP0572542B9 (en) 2001-11-21
EP0572542B1 (en) 2001-07-11
IE920556A1 (en) 1992-08-26
EP0572542A4 (en) 1994-06-01
IL100904A0 (en) 1992-11-15
HK1011281A1 (en) 1999-07-09
PT100145A (pt) 1993-08-31
HUT70489A (en) 1995-10-30
AU664545B2 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
MX9200727A (es) Composicion farmaceutica para detener el desarrollcomposicion farmaceutica para detener el desarrollo o para retardar el avance progresivo el lupus ero o para retardar el avance progresivo del lupus eritomatoso sistemico en un mamifero. itomatoso sistemico en un mamifero.
ES2186811T3 (es) Derivados de feniltiazol con propiedades anti-virus herpes.
NO983431L (no) Anti-klöemidler
ES2171888T3 (es) Composicion de aditivo para liberar un agente beneficioso y pastillas limpiadoras que contienen dichos aditivos.
ES2179862T3 (es) Utilizacion de rapamicina para el tratamiento de la anemia.
ES2196026T3 (es) Uso de ndv en la fabricacion de un medicamento para tratar el cancer.
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
BR9809951A (pt) Método para tratamento da obesidade
NO961693L (no) Delta16-umettede C17-heterocykliske steroider som er anvendbare som steroid C17-20-lyaseinhibitorer
EA199900362A1 (ru) Новые соединения, полезные для использования в качестве нейрозащитных средств
ES2069369T5 (es) Agente de mantenimiento para superficies duras.
BR9913865A (pt) Processo para revestir uma superfìcie com um agente de separação
BR0100530A (pt) Mecanismo de fricção de roda de alimentação para alimentar pelo menos um fio
BR9910365A (pt) Processo para regulagem de ignição
BR0011245A (pt) Massas de moldar de policarbonato para produção de artigos com acumulação de pó reduzida
AR006587A1 (es) Un aparato para provocar una avalancha
PT90250A (pt) Metodo para o tratamento de infeccoes de chlamydia trachomatis por aplicacao intramuscular, numa dose unica, usando uma composicao contsndo doxiciclina ou minociclina
ES2139484B1 (es) Mecanismo de rodadura para una puerta corredera.
ES2098115T3 (es) Esteres de acil l-carnitina y composiciones farmaceuticas que los contienen para tratamiento de shock endotoxico.
BR9801163A (pt) Cavilhas de expansão.
ES2185350T3 (es) Sintesis de morfina-6-glucuronido.
EA199700449A1 (ru) Способ предотвращения остеопороза
AR246374A1 (es) Un conjunto de partes para formar un sello entre un manguito y por lo menos dos sustratos
MX9204406A (es) Agente que contiene al menos un compuesto piretroide, para el control de serpientes.
CO5280204A1 (es) Uso de glutamina para la prevencion de la diarrea de inicio tardio inducida por irinotecan